Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of remibrutinib in adults with severe chronic pruritus of unknown origin
jRCT2061260047Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic pruritus comparing Remibrutinib with Placebo followed by remibrutinib (2 arms). Primary endpoint: Worst Itch Numeric Rating Scale. Started Aug 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on jRCT2061260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260047.